An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

Summary

This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.

Timeline

Start

2013-10

Primary completion

2016-02-22

Completion

2016-02-22

Drugs

Indications